Devyser has been awarded a tender for Devyser?s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital in Bologna is valid for a period of three years. Indicative order value is estimated to amount to approximately SEK 2 million annually.

Devyser?s CFTR fragment analysis products are highly sensitive CE-IVD labelled genotyping tests for detection of sequence variants in cystic fibrosis transmembrane conductance regulator (CFTR) gene. Devyser?s CFTR tests are used in the confirmation of cystic fibrosis and for screening of genetic variants in newborns and adults.